Nationwide Readmissions Database (NRD) study of 133,187 #RA pts found that 48% were "frail". Hospital readmissions were significantly higher in the RA frail pts (57% vs 31%), & hospitalized, frail patients also had significantly higher mortality (3.36% vs 0.39%) & longer LOS… https://t.co/6lF4wrC87B https://t.co/mWJGIPbEjc

A Keto Diet for Autoimmune Disorders? Scientists have long suspected the keto diet might be able to calm an overactive immune system and help some people with diseases like multiple sclerosis. https://t.co/7mX6Ue4FdX https://t.co/qtOwdKfqu4

ACIP now recommendsa pneumococcal conjugate vaccine (PCV) for all PCV-naive adults >50 yrs. Single dose of PCV (PCV15, PCV20, or PCV21) in adults >50 yrs. Pt 19-64 yrs w/ underlying conditions (prev. recommended) could recv the newly approved PCV21. https://t.co/es4KUuiYqy https://t.co/rVcIgZOLjx

In an RCT of colchicine vs PBO in #gout for 6 months shows that colchicine prophylaxis when initiating ULT did not increase the odds of achieving gout remission. https://t.co/kgNzw0UUIq https://t.co/ZdBT0Fp9Gx

Cross-sectional study of 176 CASPAR+ PsA patients correlated Dz activity (cDAPSA) w/ SAA, IL-8, IP10 (IFNg/CXCL10), M-CSF, SCGF-β, SDF-1α) (AUC 0.802- 0.835). The panel was significantly better than CRP (AUC = 0.727, p = 0.022). https://t.co/AZq81S6NH0 https://t.co/5eI241gLVj

Metanalysis of 26 RCTs suggests JAK inhibitors have a low, but signif. increased risk of infections (vs placebo) (RR 1.39; 1.096-1.76). No risk of tuberculosis or hepatitis, but an incr. risk of H. zoster was seen (RR 1.71; 0.84-3.51) https://t.co/kXOcldz46l https://t.co/Y5OWk4W1NZ

Iberdomide Efficacy in Cutaneous Lupus berdomide, a cereblon modulator that promotes degradation of transcription factors Ikaros and Aiolos, has been shown in a phase 2 trial to improve outcomes in subacute and chronic cutaneous lupus erythematosus (CLE).… https://t.co/2LtBDOIBrN https://t.co/giVDgZBiyk

Over a 16 yr span & 988 LBP referrals - 366 (37%) Dx w/ axSpA, w/ increase in # women w/ axSpA. Mean time to Dx decreased 9.8 yrs (2008) to 1 yr (2023). Greatest delay was LBP onset to GP eval. (3.2 yrs). Referral time improved by organizational change https://t.co/bEmaspJWG4 https://t.co/Jyo1neMGib

Serial MRI study of SI & lumbar (LS) joints in 24 early axSpA (Sxs < 5.5yrs) over 3 yrs, showed: - SIJ developed bone marrow edema, sclerosis & erosion. - LS: fat lesions decreased & erosions increased. - Facet joint inflammation (in t0) significantly influenced yr 3. LS bony… https://t.co/czBPVXYHYa https://t.co/6ByhsXONtf

FDA's perspective on the use of artificial intelligence in drug development. - FDA is committed to a risk-based regulatory framework that promotes innovation & protects Pt safety - Est. CDER AI Council to coordinate, develop, & support internal & external AI-related activities… https://t.co/BLCYmBBJMY https://t.co/fMie3oOfmn

An 11 yr study of 2187 #RA pts Rx w/ 3068 treatment courses of biologics or JAki, found 275 new cases of #CKD . Compared w/ CTLA4-Ig, TNFi significantly lower CKD rates (HR 0.67), whiile JAKi higher CKD rates (HR 2.16). https://t.co/2Y5BuDzJRs https://t.co/e81lOhOMjX

Save the date! RheumNows will be covering #ACR24 from 11/14-11/19. Get ready for daily recaps, live streaming and much, much, more! https://t.co/uKc14y1fOm